Compare Quest Diagnostics Inc (DGX) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI Taiwan ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while iShares MSCI Taiwan ETF trades at $114.37 (market cap $12.74B). The key difference: Quest Diagnostics Inc is far larger — about 2× iShares MSCI Taiwan ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares MSCI Taiwan ETF for 52 Days on average.
| DGX | EWT | |
|---|---|---|
Market Cap | $25.48B | $12.74B |
Volume | 941,866 | 8,470,920 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $118.00 |
52-Week Low | $173.49 | $60.03 |
Typical Hold Time | 56 Days | 52 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
EWT (iShares MSCI Taiwan ETF) trades at $114.16, down 1.79% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights Taiwan's strategic position in AI supply chains with companies planning significant US investments.
The outlook remains positive given Taiwan's dominance in semiconductor manufacturing and AI growth potential, though geopolitical risks and concentration in technology stocks present notable challenges. Institutional interest continues with Bank of America increasing its stake, supporting the ETF's long-term growth narrative despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
